OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Clinical Pharmacology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments	177
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion	56
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis	43
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed	41
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis	36
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion	30
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis	30
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions	30
Clinical pharmacology of antiplatelet drugs	30
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?	30
Reducing the risk of death – a possible outcome in COPD patients	29
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome	29
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review	29
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?	27
The pharmacotherapeutics of sarcoidosis	27
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy	27
Cannabidiol drug interaction considerations for prescribers and pharmacists	25
Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database	25
Fetal safety of medications used in treating infertility	25
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial	21
Amylin analogs for the treatment of obesity without diabetes: present and future	21
Nicotine e-cigarettes for smoking cessation: a clinical pharmacology perspective	20
Dostarlimab for the treatment of advanced endometrial cancer	20
The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease	20
Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials	20

Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection	20
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era	19
Complications related to oral corticosteroid use in asthma patients: a retrospective cohort study	19
Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients	18
Reply to: The risk for genito-urinary infections with sodium-glucose cotransporter-2 inhibitors: duration rather than dose matter?	18
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis	17
Pharmacological strategies for the management of the antisocial personality disorder	17
Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis	17
Recent pharmacological approaches for the treatment of renal cell carcinoma	17
OPTIMA-ID: development and validation of a medicine optimization tool for older adults with intellectual disability	17
Hydroxyurea in the sickle cell disease modern era	16
Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management	16
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy	16
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape	16
Effect of laparoscopic sleeve gastrectomy on drug pharmacokinetics	16
Melflufen for the treatment of multiple myeloma	16
Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia	15
Current status and prospects of IL-6–targeting therapy	15
Methenamine Hippurate in UTI management: a reemerging pharmacological strategy	15
Clinical pharmacology of SGLT-2 inhibitors in heart failure	15
Methotrexate polyglutamates	14
A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia	14
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)	14
Pharmacogenomics – a minor rather than major force in clinical medicine	14
Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis	13
Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials	13
Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis	13
Prevention of colistin induced nephrotoxicity: a review of preclinical and clinical data	13
FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?	13
Risk factors for a broken heart: understanding drug-induced causes for Takotsubo syndrome and pharmacological treatment options	13
Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of adalimumab in patients with juvenile idiopathic arthritis	13
A systematic review and meta-analysis of users versus non-users: unveiling the influence of proton pump inhibitors on capecitabine efficacy in colorectal cancer	13
Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent	12
Antimicrobial safety considerations in critically ill patients: part II: focused on anti-microbial toxicities	12
The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect	12
An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry	12
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review	12
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond	11
Efficacy and safety of dupilumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis	11
Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling	11
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis	11
Designer benzodiazepines: an update	11
Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly	11
Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression	10
Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer	10
TYK2 as a novel therapeutic target in psoriasis	10
Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review	10
Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight	10
Pharmacokinetic interaction of quetiapine and lamotrigine – victim and perpetrator?	10
Recent advances in the pharmacological management of sepsis-associated acute kidney injury	10

Golimumab retention in patients with psoriatic arthritis and axial spondyloarthritis: evidence from up to a decade of follow-up	9
Dasiglucagon for treating severe hypoglycemia in patients with diabetes	9
The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock	9
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses	9
Clinical pharmacology of siRNA therapeutics: current status and future prospects	9
Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database	9
Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerations	9
Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system	9
Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future	9
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database	9
Reliance is key to effective access and oversight of medical products in case of public health emergencies	9
Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system	9
Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia	8
Pharmacological treatment for transforming growth factor beta induced corneal dystrophies: what is the way forward?	8
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause	8
Blinding and expectancy confounds in psychedelic randomized controlled trials	8
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia	8
Clinical outcomes of oral anticoagulant discontinuation in atrial fibrillation: a systematic review and meta-analysis	8
Current understanding of the etiology of cyclic vomiting syndrome and therapeutic strategies in its management	8
Intravitreal immunotherapy in non-infectious uveitis: an update	8
Antimicrobial safety considerations in critically ill patients: part I: focused on acute kidney injury	8
The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG)	8
Inhaler technique in asthma and COPD: challenges and unmet knowledge that can contribute to suboptimal use in real life	8
Availability and evaluation of medication management resources for carers of people with dementia: a scoping review with an environmental scan	8
Clozapine for treatment refractory catatonia in individuals with autism spectrum disorder: a retrospective chart review study	8
Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to suppor	7
Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis	7
The impact of body composition on treatment in ovarian cancer: a current insight	7
Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants	7
Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges	7
The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease	7
Getting immunosuppression just right: the role of clinical biomarkers in predicting patient response post solid organ transplantation	7
Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance	7
Coadministration of silymarin with iron chelators in transfusion-dependent β-thalassemia patients: a systematic review and meta-analysis for effect on iron overload	7
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria	7
Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis	7
Novel and emerging treatment strategies for lupus nephritis	7
Epoprostenol for the treatment of pulmonary arterial hypertension	7
Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease	7
Treatment and prevention of influenza in geriatric patients	7
An overview on disease modifying and symptomatic drug treatments for multiple sclerosis	7
Emerging pharmacological strategies for treating and preventing mpox	7
Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease	7
131-I-metaiodobenzylguanidine and chemotherapy for advanced neuroblastoma	7
Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin	7
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective	7
The impact of pregnancy-related hormonal and physiological changes on antiseizure medications: expert perspective	7
Considerations when prescribing opioid agonist therapies for people living with HIV	7
The ketamine chameleon: history, pharmacology, and the contested value of experience	7
Closing the gaps in the access to quality-assured medicines for global health: The case for oxytocin for postpartum haemorrhage	7
The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis	7
Next-generation sequencing in pharmacogenomics – fit for clinical decision support?	7